Tags

Type your tag names separated by a space and hit enter

Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy.
Pediatr Infect Dis J 2000; 19(12 Suppl):S153-8PI

Abstract

OBJECTIVE

To examine the microbiologic and clinical efficacy of a 5-day course of cefdinir in the treatment of tympanocentesis-documented acute otitis media (AOM).

DESIGN

Open label noncomparative trial.

SETTING

Primary care, ambulatory.

PATIENTS

Children ages 6 months through 12 years with signs of AOM and middle ear effusion confirmed by tympanometry in at least one ear.

INTERVENTION

Patients underwent tympanocentesis at baseline and received cefdinir 7 mg/kg twice a day for 5 days.

MAIN OUTCOME MEASURES

Presumptive eradication of middle ear pathogens determined by clinical cure of signs and symptoms of AOM at end of therapy (Study Days 7 to 9) and Visit 3 (Study Days 16 to 21).

RESULTS

A total of 125 of 177 enrolled children had 134 pathogens isolated by tympanocentesis: Streptococcus pneumoniae, 69 (51.5%); Haemophilus influenzae 44 (32.8%; beta-lactamase-positive in 18 of 44 strains); beta-lactamase-positive Moraxella catarrhalis, 15 (11.2%); and Streptococcus pyogenes, 6 (4.5%). The clinical cure rates by patient in the microbiologically and overall clinically evaluable groups, respectively, were 73% (84 of 115) and 77.4% (130 of 168) at the end of therapy visit and 57.4% (66 of 115) and 61.9% (104 of 168) at Visit 3. Presumptive eradication rates at end of therapy were 8 of 11 (72.7%) and 4 of 8 (50%) for patients with penicillin-intermediate and -resistant S. pneumoniae isolates, respectively. Adverse reactions occurred in 16% of patients, with diarrhea (11%) occurring most frequently.

CONCLUSIONS

A 5-day regimen of cefdinir was effective in the eradication of the common causative pathogens of nonrefractory AOM, including intermediate penicillin-resistant S. pneumoniae and beta-lactamase-producing organisms. Cefdinir should be considered a suitable second line antibiotic for AOM.

Authors+Show Affiliations

Kentucky Pediatric Research, Bardstown, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11144397

Citation

Block, S L., et al. "Five-day Twice Daily Cefdinir Therapy for Acute Otitis Media: Microbiologic and Clinical Efficacy." The Pediatric Infectious Disease Journal, vol. 19, no. 12 Suppl, 2000, pp. S153-8.
Block SL, Hedrick JA, Kratzer J, et al. Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy. Pediatr Infect Dis J. 2000;19(12 Suppl):S153-8.
Block, S. L., Hedrick, J. A., Kratzer, J., Nemeth, M. A., & Tack, K. J. (2000). Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy. The Pediatric Infectious Disease Journal, 19(12 Suppl), pp. S153-8.
Block SL, et al. Five-day Twice Daily Cefdinir Therapy for Acute Otitis Media: Microbiologic and Clinical Efficacy. Pediatr Infect Dis J. 2000;19(12 Suppl):S153-8. PubMed PMID: 11144397.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Five-day twice daily cefdinir therapy for acute otitis media: microbiologic and clinical efficacy. AU - Block,S L, AU - Hedrick,J A, AU - Kratzer,J, AU - Nemeth,M A, AU - Tack,K J, PY - 2001/1/6/pubmed PY - 2001/5/1/medline PY - 2001/1/6/entrez SP - S153 EP - 8 JF - The Pediatric infectious disease journal JO - Pediatr. Infect. Dis. J. VL - 19 IS - 12 Suppl N2 - OBJECTIVE: To examine the microbiologic and clinical efficacy of a 5-day course of cefdinir in the treatment of tympanocentesis-documented acute otitis media (AOM). DESIGN: Open label noncomparative trial. SETTING: Primary care, ambulatory. PATIENTS: Children ages 6 months through 12 years with signs of AOM and middle ear effusion confirmed by tympanometry in at least one ear. INTERVENTION: Patients underwent tympanocentesis at baseline and received cefdinir 7 mg/kg twice a day for 5 days. MAIN OUTCOME MEASURES: Presumptive eradication of middle ear pathogens determined by clinical cure of signs and symptoms of AOM at end of therapy (Study Days 7 to 9) and Visit 3 (Study Days 16 to 21). RESULTS: A total of 125 of 177 enrolled children had 134 pathogens isolated by tympanocentesis: Streptococcus pneumoniae, 69 (51.5%); Haemophilus influenzae 44 (32.8%; beta-lactamase-positive in 18 of 44 strains); beta-lactamase-positive Moraxella catarrhalis, 15 (11.2%); and Streptococcus pyogenes, 6 (4.5%). The clinical cure rates by patient in the microbiologically and overall clinically evaluable groups, respectively, were 73% (84 of 115) and 77.4% (130 of 168) at the end of therapy visit and 57.4% (66 of 115) and 61.9% (104 of 168) at Visit 3. Presumptive eradication rates at end of therapy were 8 of 11 (72.7%) and 4 of 8 (50%) for patients with penicillin-intermediate and -resistant S. pneumoniae isolates, respectively. Adverse reactions occurred in 16% of patients, with diarrhea (11%) occurring most frequently. CONCLUSIONS: A 5-day regimen of cefdinir was effective in the eradication of the common causative pathogens of nonrefractory AOM, including intermediate penicillin-resistant S. pneumoniae and beta-lactamase-producing organisms. Cefdinir should be considered a suitable second line antibiotic for AOM. SN - 0891-3668 UR - https://www.unboundmedicine.com/medline/citation/11144397/Five_day_twice_daily_cefdinir_therapy_for_acute_otitis_media:_microbiologic_and_clinical_efficacy_ L2 - http://Insights.ovid.com/pubmed?pmid=11144397 DB - PRIME DP - Unbound Medicine ER -